Search results for "From ACP Journal Club"
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016
Studies analyze amputation rates with sodium–glucose cotransporter-2 inhibitors
An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.
https://diabetes.acponline.org/archives/2021/02/12/7.htm
12 Feb 2021
One-step screening approach detected more gestational diabetes than two-step approach but did not improve clinical outcomes
A screening approach that finds more cases of gestational diabetes without improving patient outcomes introduces considerable burden and costs to patients, clinicians, and medical systems, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/08/13/6.htm
13 Aug 2021
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
https://diabetes.acponline.org/archives/2016/08/12/6.htm
12 Aug 2016
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes
The data suggest that renoprotection from sodium-glucose cotransporter-2 (SGLT-2) inhibitors may not require the presence of diabetes or albuminuria and may be effective even in patients with worse renal function, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/03/13/6.htm
13 Mar 2020
Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea
Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.
https://diabetes.acponline.org/archives/2015/11/13/6.htm
13 Nov 2015
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
https://diabetes.acponline.org/archives/2020/01/10/8.htm
10 Jan 2020
In overweight or obese patients with diabetes, a lifestyle intervention increased weight loss at 8 years
Receiving an intensive lifestyle intervention (ILI) rather than traditional diabetes support and education (DSE) increased weight loss in about 5,000 middle-aged adults with type 2 diabetes.
https://diabetes.acponline.org/archives/2014/07/11/5.htm
11 Jul 2014